Email Article

Federal health agencies have introduced streamlined regulatory shortcuts and expanded Medicaid financing for individualized gene therapies. Under the banner of compassionate innovation, the state waives traditional clinical trial safeguards while ensuring public coffers absorb multimillion-dollar drug invoices. The arrangement transforms human affliction into a guaranteed, venture-backed annuity.